[Medullary carcinoma of the thyroid gland and the APUD system]

Medullary thyroid carcinoma, MTC, accounts for 8-10% of all thyroid malignancies. It occurs in the sporadic form (70-75%) and the familial variant (25-30%). In familial MTC the autosomal dominant type of heredity is involved. This variant is found frequently in association with other endocrine hyperplasias or tumours within the framework of the APUD system and is thus an indispensible condition of the MEN 2 syndrome, either MEN 2A (MTC and pheochromocytoma and/or hyperparathyroidism) or MEN 2B with the frequent concurrent presence of pheochromocytoma and a typical phenotype, in particular multiple neurofibromas on the lips and tongue. The type of MTC determines also to a certain extent the prognosis of the disease. MTC in the framework of MEN 2A are usually most benign, while the prognosis is poorest for MEN 2B. The sporadic variant has a poorer prognosis, as compared with differentiated thyroid carcinoma. The only effective and rational treatment of MTC is radical surgery. In all instances where we confirm the diagnosis before surgery we indicate bilateral total thyroidectomy. In the familial variant where the tumour is usually multifocal and in both lobes this indication is absolute, in sporadic forms with possible early intrathyroid dissemination of the primary tumour also to the other side, bilateral surgery is also indicated. Moreover we know that a certain ratio of assumed sporadic forms are genetically conditioned tumours and thus are familial. The histological finding of hyperplasia of the C-cells suggests the familial variant even when tumourous transformation did not occur yet.(ABSTRACT TRUNCATED AT 250 WORDS)